Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

April 10, 2020

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

April 08, 2020

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

April 07, 2020

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

April 03, 2020

Ghassan K. Abou-Alfa, MD, discusses the most intriguing updates in hepatocellular carcinoma, anticipated sequencing challenges, and novel modalities on the horizon.

April 03, 2020

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

April 02, 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

April 01, 2020

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.

April 01, 2020

Maxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.

March 30, 2020

Fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody­–drug conjugate, demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types.

March 26, 2020

Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.

March 20, 2020

Gopa Iyer, MD, discusses investigational FGFR inhibitors in metastatic urothelial carcinoma.

March 18, 2020

We recently traveled to Summit, New Jersey for a State of the Science Summit on Lung Cancer, which featured insights from Memorial Sloan Kettering Cancer Center faculty.

March 16, 2020

Ghassan K. Abou-Alfa, MD, provides perspective on the accelerated approval of nivolumab and ipilimumab in advanced hepatocellular carcinoma.

March 12, 2020

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

March 11, 2020

Chung-Han (Joe) Lee, MD, PhD, discussed advancements in metastatic renal cell carcinoma regarding combination regimens and ongoing questions of how to treat patients upon disease progression.

March 04, 2020

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.

February 22, 2020

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses

February 22, 2020

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

February 21, 2020

Martin H. Voss, MD, discusses the phase I/II trial evaluating MEDI0680 plus durvalumab in metastatic renal cell carcinoma and what similar research efforts lie ahead.

February 21, 2020

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.